Elekta AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EKTAY research report →
Companywww.elekta.com
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment.
- CEO
- Jakob Just-Bomholt
- IPO
- 2009
- Employees
- 4,541
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $2.45B
- P/E
- -598.60
- P/S
- 1.31
- P/B
- 2.93
- EV/EBITDA
- 15.08
- Div Yield
- 3.93%
Profitability
- Gross Margin
- 37.53%
- Op Margin
- 5.40%
- Net Margin
- -0.23%
- ROE
- -0.45%
- ROIC
- -2.27%
Growth & Income
- Revenue
- $18.02B · -0.57%
- Net Income
- $237.00M · -81.80%
- EPS
- $0.62 · -81.82%
- Op Income
- $890.00M
- FCF YoY
- 29.25%
Performance & Tape
- 52W High
- $6.93
- 52W Low
- $4.35
- 50D MA
- $5.98
- 200D MA
- $5.65
- Beta
- 0.96
- Avg Volume
- 1.60K
Get TickerSpark's AI analysis on EKTAY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EKTAY Coverage
We haven't published any research on EKTAY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EKTAY Report →